Navigation Links
DURECT Corporation Announces Third Quarter 2013 Financial Results and Update of Programs
Date:11/4/2013

romorphone and oxymorphone). Pain Therapeutics is now free to develop and commercialize these product candidates on its own or with a licensee. Phase I clinical trials have been conducted for ORADUR-hydrocodone and ORADUR-hydromorphone, and an Investigational New Drug (IND) application has been accepted by the FDA for ORADUR-oxymorphone. Pain Therapeutics has stated that they have not yet made a decision to develop or out-license the three product candidates.
  • Transdermal Development Candidates. We have two transdermal products that are in mid- to late-stage development with features that may be superior to currently available patches. TRANSDUR®-Sufentanil is our proprietary transdermal patch intended to deliver sufentanil to chronic pain sufferers for a period of up to 7 days from a single application; this compares favorably against existing fentanyl patches which are substantially larger and typically effective for 2-3 days. ELADUR®, for topical neuropathic conditions such as post-herpetic neuralgia (PHN), is our proprietary transdermal patch intended to deliver bupivacaine for a period of up to 3 days from a single application; existing lidocaine patches for this condition can be worn for 12 hours with a rest period of 12 hours during which time many patients experience breakthrough pain. We are in discussions with potential partners regarding licensing development and commercialization rights to these two transdermal programs for which we hold worldwide rights.
  • ORADUR-ADHD Program. We recently selected a lead formulation for the lead program in our ORADUR-ADHD (Attention Deficit Hyperactivity Disorder) program, ORADUR-Methylphenidate. This formulation was chosen based on its potential for rapid onset of action, long duration with once-a-day dosing and target pharmacokinetic profile as demonstrated in a recent Phase 1 trial. In addition, this product candidate utilizes a small capsule size relative to the
    '/>"/>

  • SOURCE DURECT Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. DURECT Corporation Invites You to Join its Third Quarter 2013 Earnings Conference Call
    2. DURECT Announces Changes to its Board of Directors
    3. DURECT Corporation Announces Second Quarter 2013 Financial Results and Update of Programs
    4. DURECT Corporation Announces First Quarter 2013 Financial Results and Update of Programs
    5. DURECT Corporation Invites You to Join its First Quarter 2013 Earnings Conference Call
    6. DURECT Corporation Invites You to Join its Fourth Quarter 2012 Earnings Conference Call
    7. DURECT Corporation Announces Third Quarter 2012 Financial Results and Update of Programs
    8. DURECT Corporation Invites You to Join its Third Quarter 2012 Earnings Conference Call
    9. DURECT to Participate in Upcoming Healthcare Conferences
    10. DURECT Corporation Announces Second Quarter 2012 Financial Results and Update of Programs
    11. DURECT Corporation Announces First Quarter 2012 Financial Results and Update of Programs
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/25/2014)... and Tobago , July 25, 2014 /PRNewswire/ ... Trinidad & Tobago Ministry of Health approved the ... that significantly increases the cure rate from Hepatitis ... with the genotype 1 virus. Telaprevir is available ... trade brand INCIVO®. Photo - ...
    (Date:7/25/2014)... July 25, 2014  Acsis Inc., the market ... serialization solutions, has recently posted an article, ... current and future needs for companies, extended supply ... supply chain model no longer work today.  The ... the growth of mobile technology, machine to machine ...
    (Date:7/25/2014)... July 25, 2014 According to ... "Global and China Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, ... Share, Growth, Trends and Forecast (Value and Volume), 2013 ... USD 19.99 billion in 2012 and is expected to ... 2019 to reach USD 32.24 billion in 2019. ...
    Breaking Medicine Technology:The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3Acsis Addresses Questions on the Modern Supply Chain 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4
    ... by March of Dimes Grantee Offers Hope for Treatment ... new gene-based,technique has successfully prevented a rare craniofacial birth ... the same disorder, according,to new research funded in part ... is being published in the journal Nature Medicine,demonstrates the ...
    ... /Xinhua-PRNewswire-FirstCall/ -- Lotus Pharmaceuticals,Inc. (OTC Bulletin Board: ... in the People,s Republic of China ("PRC"), ... in the development of,isosorbide mononitrate sustained release ... and treatment of angina., Based on ...
    Cached Medicine Technology:Molecular Therapy Succeeds in Preventing Craniofacial Birth Defect in Mice 2Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets 2Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets 3
    (Date:7/28/2014)... 28, 2014 According to the Drama Method ... relationship guide that helps women easily get the attention of ... Vkool reveals in its review that this book can teach ... their man. The book also instructs them how to conquer ... in its Drama Method review that this book is divided ...
    (Date:7/28/2014)... Dr. Alan Xenakis, MD announced today the release of ... new book, DOC X MD Funny Feelings translates ... style with humor and medical accuracy. The book is creatively ... answers to those age-old questions that most folks are embarrassed ... do mosquitoes bite some and not others? Why do folks ...
    (Date:7/27/2014)... Recently, Wdsshop.de, a reliable online supplier of women’s ... prom dresses on its website. Now, all these ... 58% off. , “We are pleased to add the new ... specially created for those who are in need of fashionable ... in style. I think our clients will love them. Ladies, ...
    (Date:7/27/2014)... shown that a powerful drug given at the time ... early risk of rejection, but that it also allows ... used after the operation. , The key results are ... the World Transplant Congress in San Francisco today. They ... the powerful combinations of treatments used to prevent early ...
    (Date:7/27/2014)... why medication to treat asthma and pneumonia can become ineffective. ... that drugs widely used to treat lung diseases work with ... which is caused by an infection, affects around 1 in ... young children, the elderly, smokers and those with an underlying ... the UK are affected by asthma and the NHS spends ...
    Breaking Medicine News(10 mins):Health News:The Drama Method Pdf Review Exposes Aaron Fox's Relationship Guide – Vkool.com 2Health News:The Drama Method Pdf Review Exposes Aaron Fox's Relationship Guide – Vkool.com 3Health News:New Book by Alan P. Xenakis, MD Reveals Mind and Body Mysteries 2Health News:Wdsshop.de Unveils New Prom Dresses To Expand The Online Market 2Health News:Kidney transplant drug halves the early risk of rejection and allows less toxic treatment 2Health News:Kidney transplant drug halves the early risk of rejection and allows less toxic treatment 3Health News:Drugs used to treat lung disease work with the body clock 2
    ... this Valentine,s Day and give the friends and family ... gift that will satisfy,their sweet tooth, warm their heart ... new Organic Chocolate Single Serve is a deep chocolate,nectar ... all of the,fat, cholesterol and calories," said Pam Dietz, ...
    ... A new company has joined the fight against MRSA ... have launched a new company, Inspiralis Ltd, based around ... enzymes that help DNA molecules to unravel and wind ... , DNA becomes tangled as a result of ...
    ... Nearly 90,000 Annual ... ... provider of,point-of-care charge capture technologies, today announced that its,customer, the ... Infusion Services Module., The Module, an extension of MedAptus, ...
    ... of Men With Erectile Dysfunction Are Smokers, NEW ... image and attractiveness, it does the exact opposite when ... According to recent studies, 60-percent of all men who ... partners burning,for more passion. In an effort to dramatically ...
    ... of the Cancion(R) System in Patients ... Hospitalized with Heart Failure, ... products company developing and marketing devices to,treat heart failure, announced ... Breaking Clinical Trial presentation at the,upcoming annual American College of ...
    ... Noyes announced today that,the firm represented The Riverside Company ... to Halyard Capital. The management team will,continue to have ... transaction,were not disclosed., "This is an excellent match ... winning healthcare and information franchise," said,Tom O,Connor, the Berkery ...
    Cached Medicine News:Health News:Give Vitasoy's 'Liquid Love' for Heart Month! 2Health News:DNA with a twist: New company to search for cancer drugs and antibiotics 2Health News:Dana-Farber Cancer Institute Completes Deployment of MedAptus' Infusion Services Module 2Health News:Dana-Farber Cancer Institute Completes Deployment of MedAptus' Infusion Services Module 3Health News:The Best Way to Stoke Your Valentine's Fire: Don't Light Up 2Health News:Orqis(R) Medical's MOMENTUM Trial Abstract Accepted for Late Breaking Clinical Trial Presentation at the American College of Cardiology Annual Meeting 2Health News:Berkery Noyes Represented The Riverside Company on the Sale of HCPro Holdings, Inc. to Halyard Capital, LLC 2Health News:Berkery Noyes Represented The Riverside Company on the Sale of HCPro Holdings, Inc. to Halyard Capital, LLC 3
    ... Pupillometry in Critical Care & Emergency ... a hand-held, cordless, and simple to use ... the measurement of the pupillary light reflex ... pupillary function which are not discernable to ...
    ...
    Inquire...
    Using proven 1064 nm technology for the treatment of deeper lesions, the Lumenis One Multi-Spot Nd:YAG module provides versatility allowing targeted treatment of leg veins, vascular lesions, facial w...
    Medicine Products: